Testing a new imaging agent for epithelial tumors
Part of Cancer clinical trials.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed or suspected tumor and are scheduled for a biopsy or surgery within 2 months.
- You are older than 18 years.
- You have adequate blood cell counts, liver function, and kidney function (your doctor will check these).
- You have at least one measurable tumor (as determined by standard scans).
- You can lie flat for at least 30 minutes, are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial uses a special PET/CT scan tracer called 68Ga-ICAM-1pep to help doctors find and stage cancers. You may be able to join if you have (or are suspected to have) certain cancers and can safely complete the scan steps.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Hear when a new Epithelial Tumors, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.